Enliven Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Enliven Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-583.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 96% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-176.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
+15%Cash, after subtracting all debt, equals 15% of its market value (net cash).
Higher than 58% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Enliven Therapeutics, Inc. made a loss over the last year. Enliven Therapeutics, Inc. owes $0.02 for every $1 it owns. Enliven Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEnliven Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.43The share price is 3.43 times Enliven Therapeutics, Inc.'s book value per share, higher than 60% of Healthcare companies in United States.
Market cap
$3.1 BThe total market value of all of Enliven Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$895 MWhat Enliven Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$12.22Net worth divided by the number of shares. The share price of $41.93 is 3.4 times this, which is the P/B above.
Return on equity (ROE)
-15.3%Enliven Therapeutics, Inc. lost 15.3% of its shareholders' money over the last year, higher than 68% of Healthcare companies in United States.
Owes vs Owns
0.02×Enliven Therapeutics, Inc. owes $0.02 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneEnliven Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossEnliven Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashEnliven Therapeutics, Inc. held $462 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Enliven Therapeutics, Inc.: $3.1 B ÷ $895 M (30 Jun 2026) = 3.4.
What is Enliven Therapeutics, Inc.'s return on equity?
Enliven Therapeutics, Inc. lost 15.3% of its shareholders' money over the last year, higher than 68% of Healthcare companies in United States.
How much does Enliven Therapeutics, Inc. owe compared with what it owns?
Enliven Therapeutics, Inc. owes $0.02 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Enliven Therapeutics, Inc. pay a dividend?
No. Enliven Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.